Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C.

Molecular Therapy

Volumn 21, Issue 9, 2013, Pages 1796-1805

  Weiland, Ola ^a   Ahlén, Gustaf ^a   Diepolder, Helmut ^b   Jung, Maria Christina ^b,c   Levander, Sepideh ^a   Fons, Michael ^d   Mathiesen, Iacob ^d   Sardesai, Niranjan Y ^d   Vahlne, Anders ^a,e   Frelin, Lars ^a   Sällberg, Matti ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF MUNICH   (Germany)

^c Department of Immu Systems ^*  (Germany)

^d Inovio Pharmaceuticals   (United States)

^e ChronTech Pharma AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONVAC C; DNA VACCINE; GAMMA INTERFERON; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; PEGINTERFERON ALPHA2A; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE RESPONSE; DELTOID MUSCLE; DNA IMMUNIZATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPORATION; FEMALE; FIRST IN HUMAN STUDY; GENOTYPE; HEPATITIS C; HUMAN; HUMAN CELL; IMMUNOGENICITY; IN VIVO STUDY; MALE; NUCLEOTIDE SEQUENCE; PAIN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

HEPATITIS C VIRUS;

ADULT; ANTIVIRAL AGENTS; COMBINED MODALITY THERAPY; ELECTROPORATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; STANDARD OF CARE; T-LYMPHOCYTES; VACCINES, DNA; VIRAL HEPATITIS VACCINES; VIRAL LOAD;

EID: 84883741031     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2013.119     Document Type: Article

References (49)

1. Diepolder, HM, Zachoval, R, Hoffmann, RM, Wierenga, EA, Santantonio, T, Jung, MC et al. (1995). Possible mechanism involving T-lymphocyte response to nonstructural protein 3 in viral clearance in acute hepatitis C virus infection. Lancet 346: 1006-1007.
2. Missale, G, Bertoni, R, Lamonaca, V, Valli, A, Massari, M, Mori, C et al. (1996). Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 98: 706-714. (Pubitemid 26349175)
3. Hultgren, C, Desombere, I, Leroux-Roels, G, Quiroga, JA, Carreno, V, Nilsson, B et al. (2004). Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responses. J Hepatol 40: 971-978. (Pubitemid 38670131)
4. Missale, G, Cariani, E, Lamonaca, V, Ravaggi, A, Rossini, A, Bertoni, R et al. (1997). Effects of interferon treatment on the antiviral T-cell response in hepatitis C virus genotype 1b-and genotype 2c-infected patients. Hepatology 26: 792-797. (Pubitemid 27392376)
5. Rohrbach, J, Robinson, N, Harcourt, G, Hammond, E, Gaudieri, S, Gorgievski, M et al.; Swiss HIV Cohort Study. (2010). Cellular immune responses to HCV core increase and HCV RNA levels decrease during successful antiretroviral therapy. Gut 59: 1252-1258.
6. Simmonds, P, Bukh, J, Combet, C, DeLeege, G, Enomoto, N, Feinstone, S et al. (2005). Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962-973. (Pubitemid 41401136)
7. Simmonds, P (2004). Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 85(Pt 11): 3173-3188. (Pubitemid 39445434)
8. Gale, M Jr and Foy, EM (2005). Evasion of intracellular host defence by hepatitis C virus. Nature 436: 939-945. (Pubitemid 41191669)
9. Bowen, DG and Walker, CM (2005). Adaptive immune responses in acute and chronic hepatitis C virus infection. Nature 436: 946-952. (Pubitemid 41191670)
10. Grakoui, A, Shoukry, NH, Woollard, DJ, Han, JH, Hanson, HL, Ghrayeb, J et al. (2003). HCV persistence and immune evasion in the absence of memory T cell help. Science 302: 659-662. (Pubitemid 37310924)
11. Franceschini, D, Paroli, M, Francavilla, V, Videtta, M, Morrone, S, Labbadia, G et al. (2009). PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest 119: 551-564.
12. Cox, AL, Mosbruger, T, Mao, Q, Liu, Z, Wang, XH, Yang, HC et al. (2005). Cellular immune selection with hepatitis C virus persistence in humans. J Exp Med 201: 1741-1752. (Pubitemid 41002893)
13. Erickson, AL, Kimura, Y, Igarashi, S, Eichelberger, J, Houghton, M, Sidney, J et al. (2001). The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 15: 883-895. (Pubitemid 34075370)
14. Serholm, J, Ahla, G, Kaul, A, Frelin, L, Alheim, M, Barnfield, C et al. (2006). Relation between viral fitness and immune escape within the hepatitis C virus protease. Gut 55: 266-274. (Pubitemid 43117288)
15. Dazert, E, Neumann-Haefelin, C, Bressanelli, S, Fitzmaurice, K, Kort, J, Timm, J et al. (2009). Loss of viral fitness and cross-recognition by CD8+ T cells limit HCV escape from a protective HLA-B27-restricted human immune response. J Clin Invest 119: 376-386.
16. Pfafferott, K, Gaudieri, S, Ulsenheimer, A, James, I, Heeg, M, Nolan, D et al. (2011). Constrained pattern of viral evolution in acute and early HCV infection limits viral plasticity. PLoS ONE 6: e16797.
17. Ruhl, M, Knuschke, T, Schewior, K, Glavinic, L, Neumann-Haefelin, C, Chang, DI et al.; East German HCV Study Group. (2011). CD8+ T-cell response promotes evolution of hepatitis C virus nonstructural proteins. Gastroenterology 140: 2064-2073.
18. Brenndfer, ED, Karthe, J, Frelin, L, Cebula, P, Erhardt, A, Schulte am Esch, J et al. (2009). Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase. Hepatology 49: 1810-1820.
19. Brenndfer, ED, Weiland, M, Frelin, L, Derk, E, Ahla, G, Jiao, J et al. (2010). Antitumor necrosis factor a treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C. Hepatology 52: 1553-1563.
20. Brenndfer, ED, Brass, A, Serholm, J, Frelin, L, Aleman, S, Bode, JG et al. (2012). Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-? production. Gut 61: 589-596.
21. Foy, E, Li, K, Wang, C, Sumpter, R Jr, Ikeda, M, Lemon, SM et al. (2003). Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 300: 1145-1148. (Pubitemid 36583099)
22. Kriegs, M, Bckstmer, T, Himmelsbach, K, Bruns, M, Frelin, L, Ahla, G et al. (2009). The hepatitis C virus non-structural NS5A protein impairs both the innate and adaptive hepatic immune response in vivo. J Biol Chem 284: 28343-28351.
23. Kasprowicz, V, Schulze Zur Wiesch, J, Kuntzen, T, Nolan, BE, Longworth, S, Berical, A et al. (2008). High level of PD-1 expression on hepatitis C virus (HCV)-specific CD8+ and CD4+ T cells during acute HCV infection, irrespective of clinical outcome. J Virol 82: 3154-3160. (Pubitemid 351329205)
24. Pawlotsky, JM (2006). Therapy of hepatitis C: from empiricism to eradication. Hepatology 43 (2 suppl. 1): S207-S220.
25. Chen, A, Ahla, G, Brenndfer, ED, Brass, A, Holmstr, F, Chen, M et al. (2011). Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3/4A-specific T cells during therapeutic vaccination. J Immunol 186: 5107-5118.
26. Plotkin, SA (2003). Vaccines, vaccination, and vaccinology. J Infect Dis 187: 1349-1359. (Pubitemid 36549679)
27. Slberg, M, Frelin, L and Weiland, O (2009). DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target. Expert Opin Biol Ther 9: 805-815.
28. Rollier, CS, Paranhos-Baccala, G, Verschoor, EJ, Verstrepen, BE, Drexhage, JA, Fagrouch, Z et al. (2007). Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology 45: 602-613. (Pubitemid 46450611)
29. Habersetzer, F, Honnet, G, Bain, C, Maynard-Muet, M, Leroy, V, Zarski, JP et al. (2011). A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology 141: 890-899.e1.
30. Kutzler, MA and Weiner, DB (2008). DNA vaccines: ready for prime time? Nat Rev Genet 9: 776-788.
31. Mathiesen, I (1999). Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 6: 508-514.
32. Ahla, G, Serholm, J, Tjelle, T, Kjeken, R, Frelin, L, Holund, U et al. (2007). In vivo electroporation enhances the immunogenicity of hepatitis C virus nonstructural 3/4A DNA by increased local DNA uptake, protein expression, inflammation, and infiltration of CD3+ T cells. J Immunol 179: 4741-4753.
33. Rice, J, Ottensmeier, CH and Stevenson, FK (2008). DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 8: 108-120. (Pubitemid 351161331)
34. Folgori, A, Capone, S, Ruggeri, L, Meola, A, Sporeno, E, Ercole, BB et al. (2006). A T-cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med 12: 190-197. (Pubitemid 43214745)
35. Dahari, H, Feinstone, SM and Major, ME (2010). Meta-analysis of hepatitis C virus vaccine efficacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 139: 965-974.
36. Leez-Labrador, FX, Berenguer, M, Sempere, A, Prieto, M, Sirera, R, Gonzez-Molina, A et al. (2004). Genetic variability of hepatitis C virus NS3 protein in human leukocyte antigen-A2 liver transplant recipients with recurrent hepatitis C. Liver Transpl 10: 217-227. (Pubitemid 38240120)
37. Ito, A, Kanto, T, Kuzushita, N, Tatsumi, T, Sugimoto, Y, Miyagi, T et al. (2001). Generation of hepatitis C virus-specific cytotoxic T lymphocytes from healthy individuals with peptide-pulsed dendritic cells. J Gastroenterol Hepatol 16: 309-316. (Pubitemid 32374847)
38. Timm, J, Lauer, GM, Kavanagh, DG, Sheridan, I, Kim, AY, Lucas, M et al. (2004). CD8 epitope escape and reversion in acute HCV infection. J Exp Med 200: 1593-1604. (Pubitemid 40094183)
39. Thomas, DL, Thio, CL, Martin, MP, Qi, Y, Ge, D, O'Huigin, C et al. (2009). Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801.
40. Bagarazzi, ML, Yan, J, Morrow, MP, Shen, X, Parker, RL, Lee, JC et al. (2012). Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 4: 155ra138.
41. Luckay, A, Sidhu, MK, Kjeken, R, Megati, S, Chong, SY, Roopchand, V et al. (2007). Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 81: 5257-5269. (Pubitemid 46744435)
42. Klade, CS, Wedemeyer, H, Berg, T, Hinrichsen, H, Cholewinska, G, Zeuzem, S et al. (2008). Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 134: 1385-1395.
43. Habersetzer, F, Baumert, TF and Stoll-Keller, F (2009). GI-5005, a yeast vector vaccine expressing an NS3-core fusion protein for chronic HCV infection. Curr Opin Mol Ther 11: 456-462.
44. McHutchison, JG, Everson, GT, Gordon, SC, Jacobson, IM, Sulkowski, M, Kauffman, R et al.; PROVE1 Study Team. (2009). Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 360: 1827-1838.
45. Castera, L, Forns, X and Alberti, A (2008). Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 48: 835-847.
46. Frelin, L, Ahla, G, Alheim, M, Weiland, O, Barnfield, C, Liljestr, P et al. (2004). Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene. Gene Ther 11: 522-533. (Pubitemid 38443519)
47. Lang, KA, Yan, J, Draghia-Akli, R, Khan, A and Weiner, DB (2008). Strong HCV NS3-and NS4A-specific cellular immune responses induced in mice and Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Vaccine 26: 6225-6231.
48. Heeg, MH, Ulsenheimer, A, Greer, NH, Zachoval, R, Jung, MC, Gerlach, JT et al. (2009). FOXP3 expression in hepatitis C virus-specific CD4+ T cells during acute hepatitis C. Gastroenterology 137: 1280-8.e1.
49. Slberg, M, Rude, U, Magnius, LO, Norrby, E and Wahren, B (1991). Rapid "tea-bag" peptide synthesis using 9-fluorenylmethoxycarbonyl (Fmoc) protected amino acids applied for antigenic mapping of viral proteins. Immunol Lett 30: 59-68.